CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{ 6-[4-(4-ETHYL-PIPERAZIN-1-YL) -PHENYLAMINO] -PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF
www.patentreply.ai/tools/patent-expiration/US9067896Important: This calculator does not include patent term extension under 35 U.S.C. § 156, which may apply to certain drug, biologic, animal drug, and medical device patents.
Learn more about PTE and patent expirationCrystalline Forms Of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl) -phenylamino] -pyrimidin-4-yl}-1-methyl-urea And Salts Thereof
Application No. 13514308
August 6, 2028
2y 48d remainingEarliest effective filing
Dec 6, 2010
+ 20 years
Dec 6, 2030
PTA +80d
Feb 24, 2031
TD cap (US 8293746)
Aug 6, 2028
Final
Aug 6, 2028
Filing Date
June 7, 2012
Earliest Effective Filing
December 6, 2010
Issue Date
June 30, 2015
PTA
+80 days
Base Expiry (before PTA)
December 6, 2030
Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors
Filing Date
Jun 23, 2008
Earliest Effective Filing
Dec 20, 2006
Issue Date
Oct 23, 2012
PTA
+595 days
Calculated Expiration
Aug 6, 2028
Crystalline Forms Of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl) -phenylamino] -pyrimidin-4-yl}-1-methyl-urea And Salts Thereof
Filing Date
Jun 7, 2012
Earliest Effective Filing
Dec 6, 2010
Issue Date
Jun 30, 2015
PTA
+80 days
Calculated Expiration
Feb 24, 2031
Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.